Understanding The UK Trials Landscape
People searching for “UK stem cell heart trials” are often hoping to find a study they can join right now. It’s an understandable hope, but the honest picture is more specific: a series of trials has already been completed and published, a compassionate programme now exists for a narrow group of patients, and a further, larger trial (Phase III) is being planned and fundraised for rather than currently open. This page sets out, in plain terms, what has actually been studied so far, what is being planned, and where to go for further information. For the full research history, see our about page.
The Trials Completed So Far
REGENERATE-AMI
This trial looked at treating patients with cell therapy within 24 hours of a heart attack. It showed, for the first time, that this was possible, and that the therapy was safe and helped the heart recover. The results have been published in medical literature.
REGENERATE-DCM
This trial treated patients with dilated cardiomyopathy, a form of heart failure. Those treated with cell therapy showed improvements in cardiac function, exercise capacity, quality of life, heart failure symptoms (NYHA class) and a biochemical marker of heart failure (NT pro-BNP). The results have been published in medical literature.
REGENERATE-IHD
This trial treated patients with ischaemic heart failure. Those treated with cell therapy showed improvements in cardiac function, heart failure symptoms, quality of life scores and the same biochemical marker, NT pro-BNP. The results have been published in medical literature.
BAMI
Carried out across Europe, BAMI was, to date, the largest clinical trial of cell therapy for heart attacks. It has been regarded as one of the most important studies in this field, with implications for future trials involving heart attack patients and cell therapy more widely. The results have been published in medical literature.
How These Trials Were Designed
Using A Patient’s Own Cells
Each trial used adult stem cells taken from the patient’s own bone marrow, rather than cells from another source. This avoids the ethical and technical issues associated with embryonic stem cells.
Why Adult Stem Cells Were Chosen
Adult stem cells are sometimes described as the body’s own building blocks, or natural repair system. Studies have suggested they may help restore damaged heart tissue, which is why they were chosen as the basis for this research programme.
What The Trials Set Out To Answer
Together, the trials were designed to find out whether this approach is safe, whether it helps the heart recover, and whether any benefit could, in time, be offered more widely. Full background on the trials is available on our clinical trials page.
From Research Into A Treatment Programme
The Compassionate Treatment Unit
Following the research trials, the Heart Cells Foundation funded the opening of a Compassionate Treatment Unit at St Bartholomew’s Hospital, London, in 2016 — the first centre of its kind in Europe. It treats a limited number of patients with heart failure on compassionate grounds, using their own stem cells.
Who This Programme Is For
The programme is for patients whose heart failure is caused by idiopathic dilated cardiomyopathy, where the heart is enlarged for no known cause, or by ischaemic heart disease due to narrowing of the coronary arteries. These are the two conditions in which the earlier REGENERATE trials showed improvement. Suitability is assessed individually; it is not available to everyone with heart failure.
How To Find Out More
Full detail on the process, and answers to common questions about who may be considered, are on our compassionate programme questions page, with an overview on the main Compassionate Unit page. If you or a family member are wondering whether this route might apply to you, please discuss it with your own cardiologist or GP first, and then contact the unit directly using the details below.
What Is Planned Next
Phase III: Planning And Fundraising
Having funded Phase I and Phase II of the Regenerate trials, the Heart Cells Foundation is now planning and fundraising for a Phase III trial. This stage is intended to build the evidence base further, with the long-term aim of this treatment being considered for wider use, including by the NHS. Phase III is not yet recruiting; it depends on funding being secured first.
Why This Step Matters
A Phase III trial, should it proceed, would be an important step towards treatment being available more widely. Until then, the compassionate programme remains the only route to treatment outside a research trial, and only for patients who meet its specific criteria.
No Trial Is Currently Open For Sign-Up
At present, there is no actively recruiting UK stem cell heart trial for new participants to join. The published trials described above are complete, and the next planned trial, Phase III, is still in the planning and fundraising stage. If this changes, details will be published on our clinical trials pages. In the meantime, anyone interested in treatment options should speak to their own cardiologist or GP, who can advise on what is clinically appropriate for their situation.
Hearing From People Who Took Part
Several patients who took part in the earlier trials or who were treated through the compassionate programme have shared their experiences in their own words, describing changes to their daily lives and activities. These accounts are personal and individual; they are not a guarantee of what any other patient might experience. You can read and watch these accounts on our patient case studies page.
Common Questions About The Trials
Can the NHS fund a place on one of these trials?
No. Research of this kind sits outside the remit of NHS funding, which is why the Heart Cells Foundation raises money independently to support it.
Where do the stem cells come from?
They are taken from the patient’s own bone marrow in a straightforward procedure, rather than from a donor or embryonic source.
Why was dilated cardiomyopathy a particular focus?
REGENERATE-DCM treated patients with this specific type of heart failure, and the results, showing improvements across several measures, have been published in medical literature.
What happens if I’m not eligible for the compassionate programme?
Eligibility is limited to the two conditions described above. If you do not meet the criteria, your cardiologist or GP remains the right person to discuss alternative treatment options with you.
How can I stay informed about Phase III?
The best way is to follow our updates or get in touch directly; details are below.
Contact
If you have questions about this research, the compassionate programme, or supporting Phase III, our team is happy to help. Please call us on 020 7935 5351, or get in touch via our contact page. You can also follow our updates on Facebook. If you are asking on behalf of a patient, please also speak to their treating cardiologist, as we are not able to give individual medical advice.
If you would like to help fund the next stage of this research, including Phase III, you can find out more on our donate page. Heart Cells Foundation is registered charity no. 1101727.
Medical Disclaimer
This page summarises published trial findings and the current status of our research and treatment programmes; it is not medical advice and should not be used to make decisions about your own treatment. Results from past trials, described here as improvements shown and published in medical literature, relate to the specific patients and conditions studied and cannot be taken as an outcome for any other individual. No trial or treatment described here is guaranteed, suitable for everyone, or available on the NHS at present. Please speak to your own cardiologist or GP about your condition and any treatment options, including whether the compassionate programme might be relevant to you.
